EPS for Dynavax Technologies Corporation (DVAX) Expected At $-0.49 as of May, 14

April 17, 2018 - By Richard Doty

Dynavax Technologies Corporation (NASDAQ:DVAX) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1. That’s change of 1.06, from 2017Q3’s 2.06. 15 investors sold all, 43 reduced holdings as Dynavax Technologies Corporation ratio dropped. 27 increased holdings while 31 funds acquired holdings. Funds hold 43.53 million shares thus 3.88% more from 2017Q3’s 41.91 million shares.
Citigroup has 0.01% invested in Dynavax Technologies Corporation (NASDAQ:DVAX). Great West Life Assurance Co Can owns 7,934 shs. Tiaa Cref Mgmt Limited Liability Company reported 0% of its capital in Dynavax Technologies Corporation (NASDAQ:DVAX). First Light Asset Ltd Liability Company, a Minnesota-based fund reported 415,573 shs. Sg Americas Securities Ltd Co owns 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 8,617 shs. Creative Planning invested in 0.02% or 230,848 shs. Mufg Americas Corp holds 0% of its capital in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1,552 shs. Pointstate Cap L P invested in 0.06% or 344,364 shs. Mhr Fund Mgmt Limited Liability Corporation, a New York-based fund reported 44,499 shs. Wall Street Access Asset Lc reported 13,300 shs or 0.39% of all its holdings. State Street owns 0.01% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 4.58 million shs. Bain Cap Pub Equity Management Lc owns 249,052 shs. Paloma Prtnrs holds 0% or 17,729 shs. Lord Abbett Ltd Liability Corporation has invested 0.03% of its capital in Dynavax Technologies Corporation (NASDAQ:DVAX). Moreover, Legal & General Public Ltd Company has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 15,220 shs.

Dynavax Technologies Corporation registered $1.07 million net activity with 0 insider purchases and 5 sales since December 13, 2017. On Thursday, March 15 a trade for 16,109 shs valued at $262,604 was made by Novack David F. On Thursday, January 4 $57,511 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) was sold by Johnson David Louis.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s earnings release is expected by WallStreet on May, 14, according to Faxor. Analysts have expectation on stock’s earnings per share of $-0.49. That’s up 12.50 % from last year’s $-0.56 earnings per share. 13.95 % negative EPS growth is what Wall Street’s predicts after $-0.43 reported EPS last quarter. The stock increased 0.80% or $0.15 during the last trading session, reaching $19.Dynavax Technologies Corporation has volume of 678,889 shares. Since April 17, 2017 DVAX has risen 231.67% and is uptrending. DVAX outperformed the S&P500 by 220.12%.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

In total 4 analysts cover Dynavax (NASDAQ:DVAX). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 8 are the (NASDAQ:DVAX)’s analyst reports since October 29, 2017 according to StockzIntelligence Inc. In Sunday, October 29 report RBC Capital Markets maintained it with “Buy” rating and $28.0 target. On Monday, January 22 the rating was upgraded by RBC Capital Markets to “Buy”. On Wednesday, February 14 the rating was downgraded by JP Morgan to “Neutral”. On Thursday, March 8 the firm earned “Buy” rating by RBC Capital Markets. On Tuesday, March 27 the stock has “Buy” rating by RBC Capital Markets. On Thursday, November 9 the firm earned “Buy” rating by Cantor Fitzgerald. On Wednesday, February 14 the firm has “Hold” rating by J.P. Morgan given. On Thursday, March 8 the firm earned “Buy” rating by Cantor Fitzgerald.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation.The firm is valued at $1.17 billion. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.Last it reported negative earnings. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

Dynavax Technologies Corporation (NASDAQ:DVAX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: